

Fact Sheet

About:

Biocon Limited, publicly listed in 2004, is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as generic formulations in the U.S. and Europe. It also has a pipeline of promising novel assets in immunotherapy under development.

Biocon Biologics is a subsidiary of Biocon Ltd. It is uniquely positioned as a fully integrated 'pure play' biosimilars organization in the world and aspires to transform patient lives through innovative and inclusive healthcare solutions. The Company's portfolio of biosimilar molecules comprises a rich pipeline of approved and in-development biosimilars, which are an outcome of its high end R&D and global scale manufacturing expertise. The Company has commercialized three of its biosimilars in the developed markets like EU, U.S., Japan and Australia. It is a leading global insulins player with over 15 years of experience in addressing the needs of patients with diabetes, having provided over 2 billion doses of human insulin worldwide, thus far.

A Credible Biopharma Enterprise:

- **7** Biologics taken from '**Lab to Market**': **2** Novels & **5** Biosimilars
- **~120** Countries where our Products are Available
- **25+** cGMP Approvals from International Regulatory Agencies*
- Ranked among **Top 10 Global Biotech Employers** by Science magazine
- **Key Brands:** INSUGEN® (rh-insulin), Basalog One® (prefilled Glargine pen), CANMAb™ (Trastuzumab), KRABEVA® (Bevacizumab), BIOMAb-EGFR® (Nimotuzumab) and ALZUMAb™ (Itolizumab)


*As of 31 March 2020

Vision

To enhance
global
healthcare
through
innovative and
affordable
biopharma
products for
patients,
partners and
healthcare
systems
across the
globe.


Revenue:

Revenue: Rs 56,588 million (FY19)



- Small Molecules
- Biologics
- Branded Formulations
- Research Services
- Other Income


Revenue: Geographic Distribution



- International
- Domestic

Global Employee Base

No. of Employees: 11,000+##



- India
- Malaysia
- Syngene

#as of March 31, 2020

Biocon at a Glance :

- First listed 'pure play' biopharmaceuticals company in India.
- First to launch an indigenously developed novel biologic in India.
- First company from India to have a biosimilar commercialized in the U.S.
- First company from India to have a biosimilar commercialized in Japan.
- World's first novel anti-CD6 monoclonal antibody to be developed and launched is Biocon's Itolizumab.
- Among world's largest producers of statin and immunosuppressant APIs globally.
- Preferred APIs partner for over 1,000 pharma companies in more than 100 countries.
- Among the largest biologics manufacturing capacity in India.
- Largest integrated insulins manufacturing complex in Asia set up by Biocon in Malaysia.




Manufacturing Locations

Bangalore | Malaysia | Hyderabad | Visakhapatnam



Growth Verticals: Aligned with Shifting Paradigms



For more information contact:

Seema Ahuja

Sr. VP & Global Head of Communications

T: +91-80-2808-2222

Email: seema.ahuja@biocon.com